Stocks to Watch: Investors will react to LIC and Delhivery's Q4 numbers. The domestic GDP data for March quarter, slated to be released later today, will also be keenly monitored.
From Sun Pharma posting loss in Q4 to Vodafone-Idea engaging in talks to raise funds, here are the top headlines on Tuesday morning
Provides for the settlement charges, says adjusted profit for Q4FY22 at Rs 1582 cr, up 18% YoY after excluding exceptional items of Rs 3,935.7 cr and one-time tax gain of Rs 76.4 cr
Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal. "We expect high single-digit top-line growth for FY23. All our businesses are positioned for growth. Ramp up in our global speciality business is expected to continue," Sun Pharma Managing Director Dilip Shanghvi said in an analyst call. He noted that markets across the globe were now in the process of normalising. "R&D investments are expected to be between 7-8 per cent of sales next year," Shanghvi noted. On its Halol-based manufacturing plant, he stated that the company will be filing its response to the FDA on the corrective actions to be undertaken to address the observations within the stipulated time. Earlier this month, the US health regulator had issued a ...
Business Standard brings you the top headlines on Monday
Sun Pharma's consolidated revenue rose 10% to Rs 9,446 cr in Q4FY22
Stocks to Watch today: JSW Steel, FSN E-Commerce Ventures (Nykaa), Jubilant Pharma, GAIL, Glenmark Pharma, Godrej Industries, PB Fintech (Policy Bazaar) will be in focus ahead of their Q4 results.
Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder
The last two years saw limited physical inspections due to travel restrictions during the pandemic
The US carries out regular inspections at offshore drug making units to ensure quality compliance. In a recent check, the US FDA has issued Form 483 to Sun Pharma Halol unit. Let's demystify Form 483
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
Business Standard brings you the top headlines on Tuesday
In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period
Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons
The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.
Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously
CLOSING BELL: Tech M, Tata Motors, BPCL, ITC, JSW Steel, PowerGrid, Bajaj Auto, Infosys, TCS, Bajaj Finserv, Bharti Airtel, Wipro and IndusInd Bank were the other gainers
Sun Pharma said it will pay Rs 5.32 crore for the stake
Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.
Rerating on the cards; the domestic business is expected to outperform